Pulmatrix和Cullgen宣布拟合并

投资界
14 Nov 2024

投资界11月14日消息,昨日,Pulmatrix(纳斯达克股票代码:PULM),一家临床阶段的生物制药公司,宣布与Cullgen达成合并协议。Cullgen是一家私有临床阶段的生物制药公司。此次拟合并旨在创建一家纳斯达克上市的公司,专注于靶向蛋白降解技术,该技术拥有三个降解剂项目,即将或正在启动I期临床试验。其中两个项目用于治疗癌症,一个项目用于治疗急性和慢性疼痛。合并后的公司预计将在合并完成时...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10